Detection of multicentric and contralateral breast cancers on MRI based on primary cancer biomarker status: will this change surgical or medical management?
| Autor: | Emily L. Sedgwick, Lilian O. Ebuoma, Tao Wang, Ana Paula Benveniste, Kenny Q. Sam, Arti R. Jonna |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Adult Cancer Research medicine.medical_specialty Biopsy Breast Neoplasms Disease 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Biomarkers Tumor Medicine Breast MRI Humans Contralateral breast skin and connective tissue diseases Aged Neoplasm Staging Retrospective Studies Aged 80 and over medicine.diagnostic_test business.industry Cancer Middle Aged medicine.disease Primary cancer Primary tumor Magnetic Resonance Imaging 030104 developmental biology 030220 oncology & carcinogenesis Biomarker (medicine) Female business |
| Zdroj: | Breast cancer research and treatment. 166(2) |
| ISSN: | 1573-7217 |
| Popis: | The utilization of staging preoperative breast MRI in biopsy-proven cancer patients varies based on institution and individual clinicians. It is unclear whether primary breast cancer subtype influences a clinician’s decision to obtain a preoperative breast MRI based on likelihood of multicentric or contralateral disease, which may change surgical or medical management. Our purpose was to compare the four main breast cancer subtypes in our patient population (i.e., luminal A, luminal B, HER2 enriched and triple-negative) who underwent pretreatment staging MRIs to determine whether certain breast cancer subtypes are more likely to have multicentric or contralateral disease. We retrospectively reviewed 435 patients with biopsy-proven invasive breast cancer who had staging MRI. Of these patients, 14 had biopsy-proven multicentric disease (3.2% of total) and 15 had biopsy-proven contralateral second tumor sites (3.4% of total). There was no statistically significant difference between primary tumor subtype and likelihood of multicentric or contralateral disease (p = 0.3065). Pretreatment staging MRI can detect multicentric and/or contralateral additional tumor sites, which ultimately changes staging, treatment options, and outcomes for patients with biopsy-proven breast cancer. There is no correlation between primary breast cancer subtype and likelihood of multicentric or contralateral disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink